
sep pm et
summari compani global research-bas pharmaceut busi key drug
humira rheumatoid arthriti indic
price-to-earnings oper ep
heavili reliant one drug humira
current account sale howev
recently-approv drug like help diversifi sale
nov ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
sep pm stock trade
see sale increas
revenu larg tie sale
blockbust drug humira revenue
expect humira sale grow
driven greater penetr
emerg market anticip launch
first biosimilar competit humira
europ
although made deal sever
larg potenti competitor delay sale
next biggest drug revenu
imbruvica expect grow
sale hepat
treatment also larg area especi
aug fda approv mavyret
report disappoint phase ii data
rova-t line treatment small cell lung
cancer base partial data
patient trial express
object respons rate well
anticip respons rate
median overal surviv
month also on-going phase
rova-t trial line set
small cell lung cancer expect
significantli lower
sep california insur
commission file complaint behalf
california alleg
commit fraud provid kickback
health care provid state think
state could also sue thu see
consider risk futur earn
potenti addit media polit
environ last year
focu lower drug price seen
recent effort govern agenc
increas viabil biosimilar drug
present anoth risk mitig
risk made deal
posit side see
strong potenti endometriosi drug orilissa
approv juli
immunolog asset upadacitinib
risankizumab given risk opportun
think share
forward earn trade near fair valu
risk target price recommend
also includ pipelin failur
target base
ep estim
multipl near mean
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview abbvi inc global research-bas drug busi emerg separ
compani follow spin-off abbott sharehold share-for-shar
basi januari compani develop market therapi address major complex
seriou diseas product focus treat condit chronic autoimmun diseas
rheumatolog gastroenterolog dermatolog oncolog includ blood cancer virolog includ
hepat viru hcv human immunodefici viru hiv neurolog disord
parkinson diseas multipl sclerosi metabol diseas includ thyroid diseas
complic associ cystic fibrosi seriou health condit compani also
pipelin new medicin clinic develop across medic specialti immunolog
oncolog neurolog addit target invest cystic fibrosi women health
key product humira inject biolog tnf tumor necrosi factor blocker treatment
rheumatoid arthriti ra similar condit estim humira account half
global prescript drug market rheumatoid arthriti besid moder sever ra adult
humira also approv mani use includ juvenil idiopath arthriti psoriasi ankylos
spondyl ulcer coliti crohn diseas axial spondyloarthr
humira composit matter patent expir end equival european union
patent set expir eu countri april competitor rheumatoid arthriti market
includ remicad market johnson johnson simponi johnson johnson enbrel
although humira patent expir decemb confid patent
surround humira number patent includ formul manufactur method
treatment abl protect biosimilar challeng least
imbruvica ibrutinib oral once-daili therapi inhibit protein call bruton tyrosin kinas
imbruvica approv treatment adult patient chronic lymphocyt leukemia cll /small
lymphocyt lymphoma sll cll/sll delet mantl cell lymphoma receiv
least one prior therapi waldenstrm macroglobulinemia margin zone lymphoma requir
system therapi receiv least one prior therapi chronic graft versu
host diseas failur one line system therapi
venclexta venetoclax approv treat peopl cll delet receiv least
one prior treatment venclexta food drug administr fda -approv treatment
target b-cell lymphoma protein support cancer cell growth overexpress major
patient cll venclexta approv eu treatment cll patient
delet mutat unsuit fail b-cell receptor pathway inhibitor
treatment cll absenc delet mutat fail
chemoimmunotherapi b-cell receptor pathway inhibitor
mavyret glecaprevir/pibrentasvir approv unit state european union maviret
treatment patient chronic hcv genotyp infect without cirrhosi
compens cirrhosi child-pugh also indic treatment adult patient hcv
genotyp infect previous treat regimen contain hcv inhibitor
proteas inhibitor eight-week pan-genotyp treatment patient
without cirrhosi new treatment
pipelin june pipelin compound indic phase ii
women health oncolog multipl sclerosi well parkinson alzheim diseas
financi trend sale increas billion billion mainli
success humira imbruvica repres three-year compound annual growth rate compound-annual-growth-rate
gross margin increas research develop
cost increas billion sale billion sale adjust
ep increas repres three-year compound-annual-growth-rate
senior vice presid
execut vice-president extern
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu
neutral sinc septemb technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit fundament outlook
biotechnolog sub-industri next
month reflect favor prospect new
novel therapi reach commerci yet
anticip modest overal
sale growth mainli due forecast
mid-teen sale declin
biotech sale rose low singl
digit follow growth
follow robust growth period
compound annual growth
rate think sale growth
somewhat limit heighten focu high
drug price encourag view
strong period report
late-stag clinic result
accommod fda approv
fda approv new drug --
sinc record approv
howev fda approv
new drug significantli robust
new drug approv think mani
newly-approv drug signific
commerci prospect repres major
advanc therapi diseas
sclerosi cancer fda
approv first time gene-therapi drug
involv remov patient immun cell
genet alter alter
cell re-introduc patient
help fight cancer
expect wider adopt biomark research
genetic-target clinic studi help
late fda introduc breakthrough
therapi design intend speed
develop promis program expect
favor merger acquisit climat
larg pharmaceut firm move off-set
lost revenu expir drug patent
larg biotech bolster drug pipelin amid
larger scale acquisit
fda author govern biosimilar
drug approv set exclus
advanc modest rate next
sever year see improv
biosimilar approv introduc
march fda approv novarti
filgrastim biosimilar version
novarti began sell
biosimilar name zarxio septemb
april fda approv
inflectra manufactur celltrion
co-market inflectra
biosimilar johnson johnson
expect biosimilar sell modest price
discount gener pharmaceut
industri due higher clinic manufactur
market cost expect brand
drug retain signific market share due
lack interchang think
biosimilar may appeal new user
expect current user stabl
current treatment would like continu
refer drug howev note
prescript benefit manag health
insur exert influenc drug
prescript price
remov neupogen formulari
replac zarxio
 biotech index rose vs
rise year date
juli biotech index
rose vs rise
base index
five-year market price perform sep
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
humira sale imbruvica expect humira sale
approach believ achiev follow patent
settlement also encourag pipelin develop
recent nda file elagolix endometriosi /jeffrey loo cfa
rais target in-lin peer
forward ep estim announc deal
regard humira litig term agreement
grant non-exclus licens humira intellectu properti
licens period begin jan oct
eu humira litig compani dismiss
pay royalti view deal posit remov
overhang world best sell drug /jeffrey loo cfa
rais target slightli peer
forward ep ep vs ahead
estim keep ep estim rais
sale rose global humira sale
 imbruvica sale rose view
pipelin posit await phase data risankizumab
psoriasi upadacitinib rheumatoid arthriti see potenti nda
file compound expect data sever trial
/jeffrey loo cfa
keep target slightli peer
ep estim ep vs in-lin
estim sale rose rise humira sale sale
intern sale imbruvica sale rose strong uptak
first line chronic lymphocyt leukemia think imbruvica gain
market share look continu robust sale imbruvica see
approv addit indic also plan submit nda
elagolix treat endometriosi later year /jeffrey loo cfa
analyst research note compani news
complaint septemb behalf state california
alleg firm violat insur fraud prevent act
provid kickback healthcar provid throughout california given
develop product concentr humira revenu
recent effort govern agenc increas viabil biosimilar
see increas risk futur earn henc lower
opinion share hold lower target
ep estim multipl near
averag three-year forward pe rang rais ep estim
lower ep look
posit catalyst see strong potenti endometriosi drug orilissa
approv juli gener immunolog asset upadacitnib
et cfra keep buy opinion share inc
keep target in-lin peer
forward ep estim ep vs
ahead view rais ep estim
ep estim sale rose humira sale
imbruvica sale hepat drug mavyret robust
see gain market share also encourag abbv pipelin
progress includ fda approv orilissa elagolix endometriosi
april nda submiss risankizumab treat psoriasi also
believ recent deal regard humira remov
overhang regard biosimilar competit grant
non-exclus licens humira begin juli
pay royalti product launch sept
enter similar deal could begin produc
biosimilar januari /jeffrey loo cfa
et cfra keep buy opinion share inc
lower target price line
peer ep estim balanc
robust growth concern rova-t compound disappoint
data phase trial third line small cell lung cancer patient data
rais concern rova-t trial on-going rova-t phase
trial first second line set small cell lung cancer ep
vs ahead estim rais ep
estim sale includ fx benefit rose
humira sale imbruvica sale spite
disappoint data rova-t view pipelin posit april
file biolog licens applic bla risankizumab treat
plaqu psoriasi expect data sever compound throughout
year begin tender offer share part
et cfra reiter buy opinion share inc
rais target peer
ep estim faster growth set
ep ep vs ahead view sale
rose humira sale imbruvica rose consist
 sale profit share encourag
result view strong pipelin guid sale
ep midpoint partli aid tax
reform see effect tax rate
rais target in-lin peer
forward ep estim ep vs
ahead view rais ep estim provid
ep guidanc line view sale grew
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
